TriangleDaratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordTREATMENT READING
Plasma Cell Neoplasms (Including Multiple Myeloma), part 3
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
98 sections
- Treatment Option Overview for Plasma Cell Neoplasms
- Asymptomatic Plasma Cell Neoplasms (Smoldering Multiple Myeloma)
- Symptomatic Plasma Cell Neoplasms
- Treatment of Amyloidosis Associated With Plasma Cell Neoplasms
- Treatment Options for Amyloidosis Associated With Plasma Cell Neoplasms
- Induction therapy
- Stem cell rescue
- Monoclonal antibody targeting of amyloid deposits
- Treatment of Monoclonal Gammopathy of Undetermined Significance
- Treatment Options for Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Watchful waiting
- Treatment of Waldenström Macroglobulinemia (Lymphoplasmacytic Lymphoma)
- Treatment of Isolated Plasmacytoma of Bone
- Treatment Options for Isolated Plasmacytoma of Bone
- Radiation therapy
- Chemotherapy
- Treatment of Extramedullary Plasmacytoma
- Treatment Options for Extramedullary Plasmacytoma
- Treatment of Multiple Myeloma
- Initial Evaluation
- Therapeutic Overview
- Indolent myeloma (smoldering multiple myeloma)
- Symptomatic myeloma
- Fit patients in good or well-controlled health
- Less-fit patients with significant comorbidities or advanced age (aged ≥80 years)
- High risk versus standard risk
- Measurable Residual Disease
- Induction Therapy
- Fit patients in good or well-controlled health
- Less-fit patients with significant comorbidities or advanced age (aged ≥80 years)
- Consolidation Therapy
- Autologous bone marrow or peripheral stem cell transplant
- Single autologous bone marrow or peripheral stem cell transplant
- Tandem autologous bone marrow or peripheral stem cell transplant followed by autologous or allogeneic transplant
- Allogeneic bone marrow or peripheral stem cell transplant
- Salvage autologous bone marrow or peripheral stem cell transplant after relapse from first transplant
- Maintenance Therapy
- Maintenance therapy (lenalidomide, ixazomib, and daratumumab alone or in combination)
- Proteasome inhibitor maintenance therapy
- Management and Prevention of Myeloma Bone Disease
- Zoledronate (bisphosphonate)
- Pamidronate (bisphosphonate)
- Denosumab (RANKL inhibitor)
- Radiation therapy for bone lesions
- Treatment of Relapsed or Refractory Multiple Myeloma
- Treatment Options for Relapsed or Refractory Multiple Myeloma
- Monoclonal antibodies
- Daratumumab
- Elotuzumab
- Isatuximab
- Proteasome inhibitors
- Bortezomib
- Carfilzomib
- Ixazomib
- CAR T-cell therapy
- Ciltacabtagene autoleucel
- Idecabtagene vicleucel (ide-cel)
- Bispecific antibody therapy
- Teclistamab
- Talquetamab
- Elranatamab
- Immunomodulatory agents
- Pomalidomide
- Lenalidomide
- Thalidomide
- BCMA-targeting antibody-drug conjugates
- Belantamab mafodotin
- Chemotherapy (cytotoxic agents)
- Selinexor
- Venetoclax
- BRAF/MEK inhibitors
- Corticosteroids
- Certain factors affect prognosis (chance of recovery) and treatment options.
- Plasma cell neoplasms may not respond to treatment or may come back after treatment.
- Treatment Option Overview
- Key Points
- There are different types of treatment for patients with plasma cell neoplasms.
- The following types of treatment are used:
- Chemotherapy
- Other drug therapy
- Targeted therapy
- High-dose chemotherapy with stem cell transplant
- Immunotherapy
- Radiation therapy
- Surgery
- Watchful waiting
- New types of treatment are being tested in clinical trials.
- New combinations of therapies
- Treatment for plasma cell neoplasms may cause side effects.
- Supportive care is given to lessen the problems caused by the disease or its treatment.
- Patients may want to think about taking part in a clinical trial.
- Patients can enter clinical trials before, during, or after starting their cancer treatment.
- Follow-up tests may be needed.
- Treatment of Monoclonal Gammopathy of Undetermined Significance
- Treatment of Isolated Plasmacytoma of Bone
- Treatment of Extramedullary Plasmacytoma
- Treatment of Multiple Myeloma
- Treatment of Relapsed or Refractory Multiple Myeloma
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Studies
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
ClinicalTrials.gov recordA Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
ClinicalTrials.gov recordStudy of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov recordReduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Recurrent Plasma Cell Myeloma
ClinicalTrials.gov recordA Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Relapsed and/or Refractory Multiple Myeloma
ClinicalTrials.gov recordA Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
ClinicalTrials.gov recordA Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
AL Amyloidosis
ClinicalTrials.gov recordA Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
Multiple Myeloma
ClinicalTrials.gov recordDaratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
ClinicalTrials.gov recordKRDI in Transplant-Eligible MM
Multiple Myeloma
ClinicalTrials.gov recordA Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
ClinicalTrials.gov recordDescartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Multiple Myeloma
ClinicalTrials.gov recordTesting Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell...
ClinicalTrials.gov recordTesting AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell...
ClinicalTrials.gov recordTesting Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordXisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
Lymphoma, Malignant Solid Neoplasm, Plasma Cell Myeloma
ClinicalTrials.gov recordA Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
AL Amyloidosis
ClinicalTrials.gov recordA Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
AL Amyloidosis
ClinicalTrials.gov recordCharacterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
Multiple Myeloma
ClinicalTrials.gov recordMGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordTo Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
Myelodysplastic Syndromes, Multiple Myeloma, Anemia
ClinicalTrials.gov recordStudy of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov recordStudy of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma
ClinicalTrials.gov recordUproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
Multiple Myeloma
ClinicalTrials.gov recordA Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordSelinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
ClinicalTrials.gov recordAcupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
Chemotherapy-induced Peripheral Neuropathy
ClinicalTrials.gov recordA Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed and/or Refractory Multiple Myeloma (RRMM)
ClinicalTrials.gov recordMAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov recordDescartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Myeloma Multiple
ClinicalTrials.gov recordTreatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
ClinicalTrials.gov recordA Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma, Multiple Myeloma
ClinicalTrials.gov recordInvestigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
ClinicalTrials.gov recordStudy of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordBelantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov recordA Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
ClinicalTrials.gov recordPersonalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Multiple Myeloma in Relapse
ClinicalTrials.gov recordA Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov recordGeriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
Multiple Myeloma, Myeloma, Disability Physical, Disabilities Multiple
ClinicalTrials.gov recordA Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
Multiple Myeloma
ClinicalTrials.gov recordUpfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordUnderstanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey
Hematologic Neoplasms
ClinicalTrials.gov recordStudy to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordMagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordMaintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
Refractory Multiple Myeloma, Relapse Multiple Myeloma
ClinicalTrials.gov recordPembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
ClinicalTrials.gov recordA Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Elranatamab, Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma, Refractory Multiple Myeloma, PF-06863135, BCMA, Bispecific, Bispecific Antibody, BCMA-CD3 Bispecific,...
ClinicalTrials.gov recordChaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant
Lymphoma, Plasma Cell Myeloma
ClinicalTrials.gov recordImmunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
ClinicalTrials.gov recordA Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordTesting Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordHome Based Daratumumab Administration for Patients With Multiple Myeloma
Plasma Cell Myeloma
ClinicalTrials.gov recordA Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordA Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordPROFAST Intervention in Precursor Multiple Myeloma
Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS, Fasting, Multiple Myeloma
ClinicalTrials.gov recordA Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease, Leukemia, Lymphoma, Cancer, Multiple Myeloma, Transplant, Age-Related Immunodeficiency
ClinicalTrials.gov recordHealth Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordFluoroquinolone Resistance Prevalence Study
Multiple Myeloma
ClinicalTrials.gov recordCOVID19 OutcomeS in Myeloma and the Impact of VaCcines
Multiple Myeloma
ClinicalTrials.gov recordA Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan
Multiple Myeloma
ClinicalTrials.gov recordIsa-Pom-Dex in Elderly/Frail Subjects With RRMM
Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity
ClinicalTrials.gov recordA Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordScalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordRepeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load
Systemic Amyloidosis
ClinicalTrials.gov recordReal-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordA Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov recordEvaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study
Chronic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Lymphoma, Malignant Solid Neoplasm, Multiple Myeloma
ClinicalTrials.gov recordPlatform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov recordTesting AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
ClinicalTrials.gov recordTesting Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
ClinicalTrials.gov recordTesting GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple...
ClinicalTrials.gov recordTesting Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
ClinicalTrials.gov recordTesting Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
ClinicalTrials.gov recordTesting Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
ClinicalTrials.gov recordTesting LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
ClinicalTrials.gov recordTesting Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
ClinicalTrials.gov recordTesting Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
ClinicalTrials.gov recordA Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Multiple Myeloma
ClinicalTrials.gov recordSub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov recordChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordJapan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordAll Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
ClinicalTrials.gov recordSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
Multiple Myeloma
ClinicalTrials.gov recordSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
Multiple Myeloma
ClinicalTrials.gov recordSub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
Multiple Myeloma
ClinicalTrials.gov recordSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
Multiple Myeloma
ClinicalTrials.gov recordSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
Multiple Myeloma
ClinicalTrials.gov recordDisease and treatment settings
Abecma: refractory Multiple myeloma after prior therapy
1 INDICATIONS AND USAGE ABECMA is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an...
advanced Multiple Myeloma
Less-fit patients with significant comorbidities or advanced age (aged ≥80 years)
advanced Plasma Cell Neoplasms
Less-fit patients with significant comorbidities or advanced age (aged ≥80 years)
AL Amyloidosis
AL Amyloidosis
Blenrep: refractory Multiple myeloma after prior therapy
Adults patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
Blenrep: refractory Multiple myeloma after prior therapy
1 INDICATIONS AND USAGE BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy,...
CARVYKTI: refractory Multiple myeloma after prior therapy
1 INDICATIONS AND USAGE CARVYKTI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory...
Darzalex Faspro: refractory Multiple myeloma after prior therapy
1.1 Multiple Myeloma DARZALEX FASPRO is indicated for the treatment of adult patients with [see Clinical Studies (14) ] : multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation...
Darzalex Faspro: refractory Multiple myeloma after prior therapy
1 INDICATIONS AND USAGE DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with...
Darzalex: refractory Multiple myeloma after prior therapy
Multiple myeloma after at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or double refractory to a proteasome inhibitor and an immunomodulatory agent
DARZALEX: refractory Multiple myeloma after prior therapy
DARZALEX is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem...
DARZALEX: refractory Multiple myeloma after prior therapy
1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell...
Elrexfio: refractory Multiple myeloma after prior therapy
Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Elrexfio: refractory Multiple myeloma after prior therapy
ELREXFIO is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T‑cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy...
EMPLICITI: Multiple myeloma after prior therapy
• EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
EMPLICITI: Multiple myeloma after prior therapy
• EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
Farydak: Multiple myeloma after prior therapy
In combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma (MM) who have received at least 2 prior regimens, including BTZ and an immunomodulatory agent.
Kyprolis: Multiple myeloma after prior therapy
Multiple myeloma after at least 2 prior therapies including bortezomib and an immunomodulatory agent and disease progression on or within 60 days of completion of the last therapy
KYPROLIS: refractory Multiple myeloma after prior therapy
( 1 , 14 ) as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
KYPROLIS: refractory Multiple myeloma after prior therapy
1.1 Relapsed or Refractory Multiple Myeloma Kyprolis is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with: Lenalidomide and...
KYPROLIS: refractory Multiple myeloma after prior therapy
1 INDICATIONS AND USAGE Kyprolis is a proteasome inhibitor that is indicated: for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with...
Lynozyfic: refractory Multiple myeloma after prior therapy
Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Multiple Myeloma
Multiple Myeloma
NINLARO: Multiple myeloma after prior therapy
1 INDICATIONS AND USAGE NINLARO ® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Pepaxto: refractory Multiple myeloma after prior therapy
In combination with dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy and whose disease is refractory to at least one...
Plasma Cell Neoplasms
Plasma Cell Neoplasms
Pomalyst: Multiple myeloma after prior therapy
Multiple myeloma after at least 2 prior therapies including lenalidomide and bortezomib and disease progression on or within 60 days of completion of the last therapy
Pomalyst: Multiple myeloma after prior therapy
1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have...
Primary Systemic Amyloidosis
Primary Systemic Amyloidosis
refractory Multiple Myeloma
Treatment of Relapsed or Refractory Multiple Myeloma
refractory Plasma Cell Neoplasms
Treatment of Relapsed or Refractory Multiple Myeloma
Sarclisa Escena: refractory Multiple myeloma after prior therapy
SARCLISA ESCENA is a CD38-directed cytolytic antibody indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including...
Sarclisa: refractory Multiple myeloma after prior therapy
SARCLISA is a CD38-directed cytolytic antibody indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide...
Talvey: refractory Multiple myeloma after prior therapy
Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
Tecvayli: refractory Multiple myeloma after prior therapy
Adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody
TECVAYLI: refractory Multiple myeloma after prior therapy
TECVAYLI is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma: in combination with daratumumab and hyaluronidase-fihj in...
XPOVIO: Multiple myeloma after prior therapy
1.1 Multiple Myeloma XPOVIO in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
XPOVIO: Multiple myeloma after prior therapy
1 INDICATIONS AND USAGE XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ).
Xpovio: refractory Multiple myeloma after prior therapy
In combination with dexamethasone for adults with relapsed/refractory multiple myeloma after at least 4 prior therapies and refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody
XPOVIO: refractory Multiple myeloma after prior therapy
In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at...
Zenbexus: Multiple myeloma after prior therapy
In combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an...
Drug labels
Abecma
ABECMA is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal...
DailyMed labelAphexda
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA, a...
DailyMed labelAPHEXDA
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA, a...
DailyMed labelBlenrep
BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome...
DailyMed labelCARMUSTINE
Carmustine for Injection, USP is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem...
DailyMed labelCARMUSTINE
Carmustine for Injection, USP is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem...
DailyMed labelCARVYKTI
CARVYKTI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are...
DailyMed labelDARZALEX
DARZALEX is indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with...
DailyMed labelDarzalex Faspro
DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib,...
DailyMed labelDOXIL
Doxil liposomal infusion is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer: After failure of platinum-based chemotherapy ( 1.1 ) • AIDS-related Kaposi’s Sarcoma: After failure of prior systemic chemotherapy or...
DailyMed labelDOXIL
DOXIL liposomal infusion is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer: After failure of platinum-based chemotherapy ( 1.1 ) • AIDS-related Kaposi’s Sarcoma: After failure of prior systemic chemotherapy or...
DailyMed labelDoxorubicin Hydrochloride Liposome
Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer: After failure of platinum-based chemotherapy ( 1.1 ) • AIDS-related Kaposi’s Sarcoma: After failure of prior...
DailyMed labelElrexfio
ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38...
DailyMed labelElrexfio
ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38...
DailyMed labelEMPLICITI
• EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. • EMPLICITI is indicated in combination with...
DailyMed labelEVOMELA
Evomela is an alkylating drug indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. ( 1.1 ) 1.1 Multiple Myeloma-Conditioning Treatment...
DailyMed labelHemady
HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM). HEMADY is a corticosteroid indicated in combination with other anti-myeloma products for the treatment of adults...
DailyMed labelIVRA
Multiple Myeloma-Palliative Treatment IVRA is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. IVRA is an alkylating drug indicated for palliative treatment of patients...
DailyMed labelKYPROLIS
Kyprolis is a proteasome inhibitor that is indicated: for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with Lenalidomide and dexamethasone;...
DailyMed labelMozobil
Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple...
DailyMed labelNINLARO
NINLARO ® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a proteasome inhibitor indicated in combination with...
DailyMed labelPlerixafor
Plerixafor is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or...
DailyMed labelSarclisa
SARCLISA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. in...
DailyMed labelSarclisa Escena
SARCLISA ESCENA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome...
DailyMed labelTALVEY
TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38...
DailyMed labelTECVAYLI
TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of therapy, including a...
DailyMed labelThalomid
• THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to...
DailyMed labelXPOVIO
XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with...
DailyMed labelZENBEXUS
ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome...
DailyMed label